Chair of pharma firm Roche advocates mandatory Covid-19 vaccination
Franz addressing an empty Roche AGM last month as shareholders were not allowed due to Covid restrictions.
Keystone / Georgios Kefalas
Christoph Franz said he was in favour of compulsory jabs if vaccination coverage rates were insufficient and if there was a social consensus on the issue.
This content was published on
2 minutes
Keystone-SDA/ac
Português
pt
Presidente de gigante farmacêutica defende vacinação obrigatória
“Solidarity is needed to overcome this crisis together,” Franz said in an interview with the Frankfurter Allgemeine Zeitung. He added that several vaccines had been developed and approved in less than a year. “That normally takes more than five years.”
The 60-year-old wanted production capacities to be built up first. “I am confident that the problems in logistics and distribution of the vaccines will be solved in the next few months,” he told the paper.
The chairman of the Swiss pharma giant was also critical of the focus on prices of vaccines by some countries. He warned that action must be taken more quickly in a pandemic because the damage to the economy is many times greater than cost savings from reducing the price of a vaccine dose.
Roche’s own pill against Covid-19 is still in the second phase of clinical development, Franz said, and has been tested in humans for efficacy and side effects. “We don’t have results yet, but we expect initial data in the next few months and hopefully results from pivotal trials this year.”
On Tuesday, the Swiss government approved the use of Regeneron’s RegN-Cov 2 drug to treat Covid-19 produced by Roche and ordered 3,000 doses of the monoclonal antibody Casirivimab/Imdevimab. The value of the contract is confidential.
Franz has been a board member of Roche since 2011 and chairman since 2014. His profile on the Roche website makes reference to his tendency to say what he thinks.
“He is an unconventional thinker who is not afraid to ask questions that (as he himself says) could turn out to be stupid.”
More
Archived
What do you think of a Covid-19 “vaccine passport” being required for activities such as travelling and going to bars and restaurants?
What do you see as the limits or benefits of this solution?
What can be done to protect biodiversity in your country?
Swiss voters are set to decide on a people’s initiative calling for better protection of ecosystems in the country. Have your say on the September 22 vote.
Swiss investigate four people linked to Russian oligarch
This content was published on
The Office of the Attorney General of Switzerland is investigating four individuals linked to Russian oligarch Suleyman Kerimov.
Swiss government scrambles to deal with egg shortage
This content was published on
From September 1, more eggs intended for consumption may be imported into Switzerland. In allowing this, the government wants to secure the supply of eggs for consumers.
This content was published on
Agricultural research sees new development opportunities for Swiss sparkling wines in the face of declining wine consumption. In a survey, half of consumers expressed a willingness to pay more for local products than for foreign ones.
Locarno spotlights filmmakers from South America and Caribbean
This content was published on
The Open Doors section of the Locarno Film Festival has named the winners for 2024. The spotlight is on the South American and Caribbean regions.
Storm paralyses trains to popular Swiss tourist resort
This content was published on
The railway line between Zweilütschinen and Grindelwald in central Switzerland is expected to remain closed until Friday following heavy rains.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Switzerland in race for sufficient Covid immunisation
This content was published on
Health authorities have called for an extra effort from the Swiss population to keep Covid infections as low as possible in the next few months.
This content was published on
With its big bet on data and digitilisation, Roche has its eye on a new crop of specialists. Now it just needs to woo them.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.